

This issue's topics



Molecular imaging - an explosion of new information

Given the advances that have been made in the development and application of imaging techniques, particularly in the field of oncology, in 2000, it was proposed that a Special Issue based on “state of the art” information would be fruitful. This issue is a result of that proposal and new diagnostic methodologies as diverse as magnetic resonance imaging, positron emission tomography, computed tomography, ultrasound, luminescence imaging (to name a few) are examined and discussed. We hope that our readers will be both informed and excited by the data within this issue and the future prospects for the use of such techniques. For a more detailed description of the content, we refer the reader to the list of contents.

Forthcoming papers

Editorial Comments

Editorial Comment on “A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy by Schmitt *et al*”

Hayward RL, Smyth JF

Statement

The Statement of Barcelona. The Future of Breast Cancer Research in Danger

Baum M, Buchanan M, Baselga J, Cataliotti L, Jassem J, Piccart M

Review

Mouse models to study the role of telomeres in cancer, aging and DNA repair

Blasco Maria A

New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections

von Knebel Doeberitz M

Original papers

Clinical

Neoadjuvant chemotherapy for Ewing's tumour of bone: recent experience at the Rizzoli Orthopaedic Institute

Bacci G, Mercuri M, Longhi A *et al*.

Soluble adhesion molecules (E-selection, ICAM-1 and VCAM-1) in breast carcinoma

O'Hanlon DM, Fitzsimons H, Lynch J *et al*.

Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases

McKay JA, Murray LJ, Curran S *et al*.

Neoadjuvant endocrine therapy of breast cancer: a surgical perspective

J M Dixon, T J Anderson, W R Miller

Adjuvant endocrine treatment with medroxyprogesterone acetate or Tamoxifen in stage I and II endometrial cancer - a multicentre, open, controlled, prospectively randomised trial

von Minckwitz G, Loibl S, Brunnert K *et al*.

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH66336 given once daily to patients with advanced solid tumours

Awada A, Eskens FALM, Piccart M *et al.*

Epirubicin vs CMF as adjuvant therapy for Stage I and II Breast Cancer: a prospective randomised study

Colozza M, Bisagni G, Mosconi AM, Gori S, Boni C, Sabbatini R, Frassoldati A, Passalacqua R, Rosa Bian A, Rodino C, Rodini E, Algeri R, Di Sarra S, De Angelis V, Cocconi G, Tonato M on behalf of the GOIRC

Paediatric

Announcement

Differing levels of cyclin-dependent kinase inhibitors in embryonal and alveolar rhabdomyosarcomas

Moretti A, Borrielo A, Monno F *et al.*

Epidemiology and Cancer Prevention

Meat consumption and meat preparation in relation to colorectal adenomas among sporadic and HNPCC family patients in the Netherlands

Voskuil DW, Kampman E, Grubben MJAL *et al.*

Experimental

Retention of activity in four human tumour cell lines possessing acquired resistance to oxaliplatin by the new generation platinum agent ZD0473

Sharp SY, O'Neill CF, Rogers P *et al.*

Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumour growth potential and results in an increased sensitivity to anticancer agents in human colon cancer

Yamamoto T, Manome Y, Nakamura M, Tanigawa N

Detection of circulating cells expressing *chromogranin a* gene transcripts in patients with lung neuroendocrine carcinoma

Begueret H, Vergier B, Begueret J *et al.*